Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
VANCOUVER, British Columbia, March 13, 2017 -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that management will host a conference call and audio webcast on Wednesday, March 15, 2017 at 8:30 a.m. Eastern Time to provide a business update and review preliminary fourth quarter and full year 2016 financial results.
To participate, please dial (866) 516-3002 (domestic) or (760) 298-5082 (international). A live webcast will be available in the “Investors” section of Novelion’s website, www.novelion.com, and a replay will be available for 90 days after the conclusion of the event.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the potential treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.
CONTACT: Amanda Murphy, Director, Investor & Corporate Communications Novelion Therapeutics 857-242-5024 [email protected]
